203 related articles for article (PubMed ID: 29784741)
1. Management of Multiple Myeloma.
Kumar SK
J Natl Compr Canc Netw; 2018 May; 16(5S):624-627. PubMed ID: 29784741
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
3. Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion.
Kitamura H; Kubota Y; Yamaguchi K; Kamachi K; Nishioka A; Yokoo M; Shindo T; Ando T; Kojima K; Kimura S
Intern Med; 2018 Mar; 57(6):855-860. PubMed ID: 29151530
[TBL] [Abstract][Full Text] [Related]
4. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Venner CP; Connors JM; Sutherland HJ; Shepherd JD; Hamata L; Mourad YA; Barnett MJ; Broady R; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Nitta J; Power MM; Toze CL; Smith CA; Song KW
Leuk Lymphoma; 2011 Jan; 52(1):34-41. PubMed ID: 21133716
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.
Sidiqi MH; Aljama MA; Bin Riaz I; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Rajkumar SV; Kumar SK; Gertz MA
Blood Cancer J; 2018 Nov; 8(11):106. PubMed ID: 30409963
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
7. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Bumma N; Dhakal B; Fraser R; Estrada-Merly N; Anderson K; Freytes CO; Hildebrandt GC; Holmberg L; Krem MM; Lee C; Lekakis L; Lazarus HM; Mian H; Murthy HS; Nathan S; Nishihori T; Parrondo R; Patel SS; Solh M; Strouse C; Vesole DH; Kumar S; Qazilbash MH; Shah N; D'Souza A; Sidana S
Cancer; 2023 Jul; 129(14):2179-2191. PubMed ID: 37021929
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
9. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Rajkumar SV
Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV
Am J Hematol; 2022 Aug; 97(8):1086-1107. PubMed ID: 35560063
[TBL] [Abstract][Full Text] [Related]
12. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
13. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R
Cochrane Database Syst Rev; 2012 Oct; 10():CD004626. PubMed ID: 23076906
[TBL] [Abstract][Full Text] [Related]
14. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
15. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Nishihori T; Alsina M
Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
[TBL] [Abstract][Full Text] [Related]
16. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
[TBL] [Abstract][Full Text] [Related]
17. Current approaches to management of newly diagnosed multiple myeloma.
Goel U; Usmani S; Kumar S
Am J Hematol; 2022 May; 97 Suppl 1():S3-S25. PubMed ID: 35234302
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Sonneveld P; Avet-Loiseau H; Lonial S; Usmani S; Siegel D; Anderson KC; Chng WJ; Moreau P; Attal M; Kyle RA; Caers J; Hillengass J; San Miguel J; van de Donk NW; Einsele H; Bladé J; Durie BG; Goldschmidt H; Mateos MV; Palumbo A; Orlowski R
Blood; 2016 Jun; 127(24):2955-62. PubMed ID: 27002115
[TBL] [Abstract][Full Text] [Related]
19. Advances in therapy of multiple myeloma.
Bladé J; Rosiñol L
Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
[TBL] [Abstract][Full Text] [Related]
20. Multiple Myeloma in the Time of COVID-19.
Al Saleh AS; Sher T; Gertz MA
Acta Haematol; 2020; 143(5):410-416. PubMed ID: 32305989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]